Rhythm reports $92.1M Imcivree revenue as US momentum grows
Rhythm Pharmaceuticals reported Q3 net product revenue of $92.1 million, a 29% sequential increase, and announced a secured five-year loan facility.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed